Daniel F Donovan III (Dan)

Representative Experience

• Representing a variety of clients with congressional investigations by House and Senate committees, including consumer products, healthcare, pharmaceutical and medical device clients in connection with investigations relating to product safety, product pricing, clinical research, off-label promotion, direct-to-consumer advertising, payments to physicians, and allegations of government fraud.
  
  
• Representing Toyota in connection with House and Senate committee investigations relating to allegations of unintended acceleration.
  
  
• Representing a home healthcare and hospice services company in connection with Senate committee inquiry into Medicare reimbursement.
  
  
• Representing a Big Four accounting firm in a Senate committee investigation of a University’s handling of federal funds.
  
  
• Representing pharmaceutical trade association in connection with ongoing and potential congressional oversight.
  
  
• Representing GlaxoSmithKline in connection with House and Senate committee investigations.
  
  
• Representing Pfizer Inc in connection with House and Senate committee investigations.
  
  
• Representing medical device companies in connection with Senate committee investigations into 510(k) regulatory issues, direct-to-consumer advertising and payments to physicians.
  
  
• Representing a healthcare insurance company in connection with House and Senate committee investigations into insurance rates.
  
  
• Representing a medical society in connection with Senate committee investigations in payments to physicians.
  
  
• Representing a global medical products company in connection with House and Senate committee investigations related to contaminated Heparin and foreign manufacturing facilities.
  
  
• Representing non-profit entity in connection with Senate committee inquiries.
  
  
• Represented a government contractor with respect to the Federal Emergency Management Agency’s) post-Hurricane Katrina emergency response.
  
  
• Represented a Medicare insurance company and major pharmaceutical companies in connection with House committee requests for information regarding Part D prescription drug pricing.
  
  
• Represented a pharmaceutical company in connection with State Attorney General investigation regarding alleged “off-label” promotion, and other sales, marketing and development activities.
  
  
• Represented individuals in connection with House and Senate committee inquiries.